SANOFI-HAF78



Immunogenicity and Safety of Sanofi Pasteur’s AVAXIM 80U Pediatric Vaccine Administered in Healthy Adolescents, Children and Toddlers in People’s Republic of China Followed by a Booster Dose 6 Months after the Initial Dose Versus HAVRIX 720 Vaccine
Hepatitis A vaccine, Inactivated
HAF78
NCT00483470
Active immunisation against Hepatitis A infection
Phase 3
 
Datasets and document are available as per Sanofi Policy and criteria
December 2017